{
    "clinical_study": {
        "@rank": "45313", 
        "arm_group": {
            "arm_group_label": "SmartPill Monitoring System", 
            "arm_group_type": "Experimental", 
            "description": "patients with symptoms of Gastroparesis will undergo the SmartPill monitoring system test"
        }, 
        "brief_summary": {
            "textblock": "This protocol is designed to validate use of the SPM for diagnosis of delayed gastric\n      emptying in patients with symptoms of gastroparesis and assess impact of a SmartPill study\n      on patient management in the gastroparetic populations.  Patients with symptoms of\n      gastroparesis will be recruited.\n\n      Patients will undergo concurrent gastric scintigraphy and SPM testing to determine the\n      presence or absence of delayed gastric emptying based on predetermined diagnostic cutoffs\n      for each technique."
        }, 
        "brief_title": "Clinical Management With SPM System and Validation of the SPM 5 Hour Cutoff in Patients With Symptoms of Gastroparesis", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastroparesis", 
        "condition_browse": {
            "mesh_term": "Gastroparesis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females between ages of 18-80 years of age with symptoms of gastroparesis\n             for at least 12 weeks.\n\n          -  Presenting with 2 or more of the following symptoms or signs which, in the opinion of\n             the site investigator, are suggestive of a diagnosis of gastroparesis:\n\n               -  1 Nausea, vomiting, or retching (dry heaves)\n\n               -  2 Postprandial fullness or early satiety\n\n               -  3 Bloating or visible abdominal distention\n\n               -  4 Postprandial discomfort or pain\n\n          -  Ability to stop proton pump inhibitors for 7 days and histamine2 receptor\n             antagonists, prokinetic agents, narcotic agents, anticholinergic drugs, and\n             cannabinoids 3 days prior to SPM and gastric scintigraphy testing.\n\n          -  No evidence of metabolic disease (hypothyroidism, uncontrolled diabetes [hemoglobin\n             A1c >10% within the past 6 months], electrolyte imbalance).\n\n          -  An upper endoscopy or upper gastrointestinal barium series within the past 2 years\n             showing no organic disease that is potentially causative of symptoms.\n\n          -  High probability of compliance and completion of study.\n\n        Exclusion Criteria:\n\n          -  Participation in previous SmartPill clinical trials.\n\n          -  Previous history of bezoars (the presence of retained liquid, bile, or small amounts\n             of poorly organized food residue is permitted).\n\n          -  Dysphagia to solid food or pills.\n\n          -  Prior surgery involving the luminal gastrointestinal tract (cholecystectomy,\n             appendectomy, and hysterectomy are permitted if performed > 3 months prior to SPM\n             test).\n\n          -  Any abdominal or pelvic surgery within the past 3 months\n\n          -  Known or history of inflammatory bowel disease.\n\n          -  History of diverticulitis, diverticular stricture, and other intestinal strictures.\n\n          -  Chronic daily use of nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen, etc.)\n\n          -  Tobacco or alcohol use within eight hours prior to capsule ingestion.\n\n          -  BMI > 40 kg/m2.\n\n          -  Allergies to eggs, bread, or jam.\n\n          -  Females of childbearing age who are not practicing birth control and/or are pregnant\n             or lactating.  (Urine pregnancy testing will be performed on female subjects of\n             child-bearing potential prior to capsule ingestion and gastric scintigraphy).\n\n          -  Use of cardiac medical devices such as pacemakers and defibrillators (gastric\n             stimulators, bladder stimulators, spinal stimulators, medication infusion devices,\n             insulin pumps, continuous glucose monitors are permitted).\n\n          -  Uncontrolled diabetes with a hemoglobin A1c >10%.\n\n          -  Patient is expected to undergo MRI examination within 7 days after ingestion of the\n             capsule"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02022826", 
            "org_study_id": "MA-501"
        }, 
        "intervention": {
            "arm_group_label": "SmartPill Monitoring System", 
            "intervention_name": "SmartPill Monitoring System", 
            "intervention_type": "Device", 
            "other_name": "SPM"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Gastroparesis", 
            "SmartPill Monitoring System (SPM)", 
            "Gastric Emptying Scintigraphy (GES)"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Palo Alto", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University"
                }, 
                "investigator": {
                    "last_name": "Linda Nguyen, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Largo", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33777"
                    }, 
                    "name": "Florida Digestive Health"
                }, 
                "investigator": {
                    "last_name": "Michael Schulman, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Augusta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30909"
                    }, 
                    "name": "Georgia Regents University"
                }, 
                "investigator": {
                    "last_name": "Satish S.C. Rao, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University"
                }, 
                "investigator": {
                    "last_name": "John Wo, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "investigator": {
                    "last_name": "Braden Kuo, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "University of Michigan"
                }, 
                "investigator": {
                    "last_name": "William Hasler, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19140"
                    }, 
                    "name": "Temple University"
                }, 
                "investigator": {
                    "last_name": "Henry Parkman, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37421"
                    }, 
                    "name": "Clinsearch,LLC"
                }, 
                "investigator": {
                    "last_name": "Richard Krause, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "El Paso", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "79905"
                    }, 
                    "name": "Texas Tech University"
                }, 
                "investigator": {
                    "last_name": "Richard McCallum, Prof.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burlington", 
                        "country": "United States", 
                        "state": "Vermont", 
                        "zip": "05401"
                    }, 
                    "name": "Fletcher Allen Health Care"
                }, 
                "investigator": {
                    "last_name": "Allen Lee, Dr.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Clinical Management With SmartPill Motility Monitoring System and Validation of the SmartPill Five Hour Cutoff in Patients With Symptoms of Gastroparesis", 
        "overall_contact": {
            "email": "bkuo@partners.org", 
            "last_name": "Braden Kuo, Dr."
        }, 
        "overall_official": {
            "last_name": "Braden Kuo, Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Per patient device agreement for the diagnosis of delayed gastric emptying between SmartPill Motility Monitoring System (SPM) gastric emptying time (GET >5 hours) and the non-reference standard, gastric Emptying scintigraphy test (>10% retention of a solid meal at 4 hours) in patients with symptoms of gastroparesis", 
            "measure": "Per patient device agreement between SmartPill Motility Monitoring System gastric emptying time & gastric Emptying scintigraphy test in patients with symptoms of gastroparesis", 
            "safety_issue": "No", 
            "time_frame": "an expected average of two weeks from study procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02022826"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Agreement between Gastric emptying time of SmartPill capsule (GET>8hrs= severe) and gastroduodenal contractility (36)  and percent of radiolabeled meal retained at  4 hours on scintigraphy (>35% = severe)", 
            "measure": "Agreement between Gastric emptying time of SmartPill capsule and gastroduodenal contractility and percent of radiolabeled meal retained at  4 hours on scintigraphy", 
            "safety_issue": "No", 
            "time_frame": "an expected average of two weeks from study procedure"
        }, 
        "source": "Given Imaging Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Given Imaging Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}